Conference abstract · 14 Sep 2017
Conference abstract
Ab-proteases as unique biomarkers and biopredictors to monitor chronic inflammation of autoimmune origin at subclinical and clinical stages
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Abs against myelin basic protein (MBP), cardiac myosine (CM) and thyroid Ags (TPO, T3 and T4) endowing with proteolytic activity (Ab-proteases) are of great value to monitor chronic auto-immune inflammation and to thus illustrate the evolution of either of the above-mentioned auto-immune disorders. Ab-proteases from MS, AIM and AIT patients exhibited specific proteolytic cleavage of MBP, CM and thyroid Ags (T3, T3, TPO), respectively. The activity of the Ab-proteases markedly differs between: (i) the patients and healthy controls, and (ii) different clinical courses, to predict transformation prior to changes of the clinical course. The activity of Ab-proteases was first registered at the subclinical stages 1-5 years (regardless to type of the disor-der) prior to the clinical illness. Some (12-24%) of the direct disease-related relatives are sero-positive for low-active Ab-proteases from which seropositive relatives established were being monitored for 2-3 years whilst demonstrating a stable growth of the Ab-associated proteolytic activity. We saw also low-active Ab-proteases in persons at MS-, AIM- and AIT-related risks (at the subclinical stages), and primary clinical, ultrasonic and MRT manifestations observed were coincided with the activity to have its mid-level reached. The activity of Ab-proteases would confirm a high subclinical and predictive value of the translational tools as applicable for personalized monitoring protocols. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism. Of tremendous value are Ab-proteases directly affecting the physiologic remodeling of tissues with multilevel architecture. Further studies on targeted Ab-mediated proteolysis may provide a supplementary tool for predicting exacerbations and thus the disability of the MS, AIM and AIT patients.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 1 Sep 2015
Tissue-specific autoimmune disorders: Antibody-proteases as a generation of highly informative and unique biomarkers to monitor subclinical and clinical stages of demyelination in multiple sclerosis (MS)
Conference abstract · 28 Nov 2016
Abzymes as highly informative and unique biomarkers of the newest generation to monitor chronic autoimmune disorders at subclinical and clinical stages to predict features of the course
Conference abstract · 1 Sep 2015
PPPM as a model of healthcare services to operate biomarkers of newer generations to monitor clinical and subclinical stages of chronic inflammatory conditions of autoimmune origin
Conference abstract · 1 Sep 2015
Systemic autoimmune disorders: SLE and RA as an illustration of the clinical and predictive value of DNA-abzymes as unique biomarkers of newer generation to monitor the disorders at subclinical and clinical stages and to manage the disorders
More from this journal
The newest in Journal of Pharmacogenomics & Pharmacoproteomics.
Article · 31 Dec 2025
Molecular Phenotyping: Integrated Biological Profiles for Understanding Cellular Function and Disease
Article · 31 Dec 2025
Genetic Determinants of Individual Drug Response
Article · 31 Dec 2025
Genetic Variation in Drug Metabolism, Transport, and Treatment Response
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacogenomics & Pharmacoproteomics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Sergey Suchkov”
